MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

InflaRx NV

Atidarymo kaina

1.31 6.5

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.23

Max

1.35

Pagrindiniai rodikliai

By Trading Economics

Pajamos

12M

-5.1M

Pardavimai

-124K

-423

Pelnas, tenkantis vienai akcijai

-0.08

Pelno marža

1,208,456.738

Darbuotojai

74

EBITDA

12M

-5M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+481.06% upside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-4.7M

77M

Ankstesnė atidarymo kaina

-5.19

Ankstesnė uždarymo kaina

1.31

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bullish Evidence

InflaRx NV Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-04-24 23:54; UTC

Karštos akcijos

Stocks to Watch: Alphabet, Intel, AppFolio

2025-04-24 23:51; UTC

Rinkos pokalbiai

Gold Edges Higher, Supported by U.S. Dollar Weakness -- Market Talk

2025-04-24 23:46; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-04-24 23:46; UTC

Rinkos pokalbiai

Nikkei May Rise on Hopes for Easing U.S.-China Trade Tensions -- Market Talk

2025-04-24 23:37; UTC

Svarbiausios naujienos

Big Tech Braces for Tariff-Induced Advertising Slowdown -- WSJ

2025-04-24 23:36; UTC

Svarbiausios naujienos

Tokyo Consumer Inflation Accelerates in April as Companies Raise Prices

2025-04-24 23:13; UTC

Svarbiausios naujienos
Uždarbis

Google's Earnings Power Holds Up in Global Turbulence -- Update

2025-04-24 23:09; UTC

Svarbiausios naujienos

Trump Initiatives Knocked Back in a New Round of Court Rulings -- 2nd Update

2025-04-24 23:02; UTC

Įsigijimai, susijungimai, perėmimai

SK Telecom to Sell 10.8M Kakao Shares via After-Hours Block Trading

2025-04-24 23:02; UTC

Įsigijimai, susijungimai, perėmimai

SK Telecom to Dispose of 2.4% Stake in Kakao to Raise KRW413.27B

2025-04-24 22:51; UTC

Svarbiausios naujienos
Įsigijimai, susijungimai, perėmimai

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update

2025-04-24 22:48; UTC

Svarbiausios naujienos

Walmart Walks the DEI Tightrope in Latest Proxy Statement -- Barrons.com

2025-04-24 22:47; UTC

Rinkos pokalbiai

Intel Remains in Tough Position, CFRA Research Analyst Says -- Market Talk

2025-04-24 22:38; UTC

Rinkos pokalbiai
Uždarbis

Tariffs Hurt Intel's 2Q Outlook as CFO Warns Economic Slowdown is Likely -- Market Talk

2025-04-24 22:24; UTC

Uždarbis

Aluminum Corp. of China: Increase in Product Sales Supported 1Q Results >2600.HK

2025-04-24 22:24; UTC

Uždarbis

Aluminum Corp. of China 1Q Rev CNY55.78B Vs. CNY48.96B >2600.HK

2025-04-24 22:24; UTC

Rinkos pokalbiai
Uždarbis

Intel's Comeback Involves More Engineers, More In-Office Work -- Market Talk

2025-04-24 22:23; UTC

Uždarbis

Aluminum Corp. of China 1Q Net CNY3.54B Vs. Net CNY2.23B >2600.HK

2025-04-24 22:11; UTC

Rinkos pokalbiai
Uždarbis

Global Equities Roundup: Market Talk

2025-04-24 22:11; UTC

Rinkos pokalbiai
Uždarbis

Intel CEO: Layoffs Will Simplify Company Structure -- Market Talk

2025-04-24 22:09; UTC

Svarbiausios naujienos
Uždarbis

Intel Cuts Outlook, Says Layoffs Are in Store -- Update

2025-04-24 22:00; UTC

Rinkos pokalbiai
Uždarbis

T-Mobile's Key Subscriber Metric Disappoints Despite Earnings Beat -- Market Talk

2025-04-24 21:39; UTC

Svarbiausios naujienos

Trump Initiatives Knocked Back in a New Round of Court Rulings -- WSJ

2025-04-24 21:24; UTC

Svarbiausios naujienos
Uždarbis

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

2025-04-24 21:24; UTC

Svarbiausios naujienos
Uždarbis

Google's Earnings Power Holds Up in Global Turbulence -- WSJ

2025-04-24 21:23; UTC

Svarbiausios naujienos
Uždarbis

Intel Cuts Outlook, Says Layoffs Are in Store -- WSJ

2025-04-24 21:04; UTC

Uždarbis

T-Mobile Reports Strong Earnings but Its Wireless Results Disappoint. The Stock Is Sliding. -- Barrons.com

2025-04-24 21:03; UTC

Uždarbis

Agnico-Eagle Mines Believes Its Rev Structure Will Be Largely Unaffected by the Tariffs >AEM.T

2025-04-24 21:03; UTC

Uždarbis

Agnico-Eagle Mines Total Expected Capex for 2025 Still Estimated at $1.75 B to $1.95 B >AEM.T

2025-04-24 21:02; UTC

Uždarbis

Agnico-Eagle Mines Positioned to Achieve 2025 AISC Per Ounce Guidance of $1,250 to $1,300. >AEM.T

Akcijų palyginimas

Kainos pokytis

InflaRx NV Prognozė

Kainos tikslas

By TipRanks

481.06% į viršų

12 mėnesių prognozė

Vidutinis 7.67 USD  481.06%

Aukščiausias 10 USD

Žemiausias 5 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines InflaRx NV kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

4 ratings

3

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

1.1 / N/APalaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bullish Evidence

Vidutinės trukmės periodas

Strong Bearish Evidence

Ilgalaikis periodas

Bearish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę InflaRx NV

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.